![](https://nea.imgix.net/files/employee/Paul-Walker.png?bg=%23ddd&facepad=3&fit=facearea&fp-x=0.5&fp-y=0.5&h=552&ixlib=php-2.1.1&w=552&s=37e1f31888b7abeaf72780740160db3c)
Paul joined NEA in 2008. He focuses on later-stage life sciences investments. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst (CFA) designation. He is a Director of Allakos (NASDAQ: ALLK), TRACON Pharmaceuticals (NASDAQ: TCON), and Trillium Therapeutics (NASDASQ: TRIL); he was previously a Director of TESARO (NASDAQ: TSRO) and manages a number of NEA’s public healthcare investments.